Research Portal

3 EasyResearch Stock Pics to start your week


Stock Picks

2021 is off to the races and much like the start of 2020, it is still filled with uncertainty which could lead to unprecedented investment opportunities in the long run.

The next “Bull Run” might only be beginning to stretch its legs for 2021. With additional stimulus by the Biden presidency and lower interest rates from the U.S Fed, the U.S economy should be on fire.

EasyResearch looks at 3 stocks to get your week going! 

Click logos to view shares

on EasyEquities

New call-to-actionNew call-to-actionNew call-to-action

Teladoc Health Inc. (TDOC)

The virtual healthcare service, Teledoc has changed the way we view healthcare and was one of the COVID-19 pandemic investment standouts. The share price has increased a 165% over the last year and might continue to shine even after the pandemic. Physicians can fit in more patience virtually and patients understand the convenience of “telemedicine” moving forward.

Teledoc’s latest acquisition of Livongo Health could also be a game changer as Teledoc could cross sell services which should boast well for the bottom line.

NIO Limited (NIO)

Electric vehicle (EV) companies are in a race to take market share from Tesla Inc and the Chinese premium EV maker NIO Limited is no different. The company competes with the likes of Volkswagen AG, Daimler AG and Bayerische Motoren Werke AG.

The company recently unveiled its planes on a new luxury sedan with horsepower to rival Porsche, autonomous driving, and a higher capacity battery. “NIO is building out a battery-swapping network. NIO, throughout its history, has endeavored to solve EV problem such as range anxiety and charge time by swapping out the entire battery back.” – Al Root

The company is also considering entering the mass market under a different brand as EV technology advances and battery cost lowers.

ARK Genomic Revolution ETF (ARKG)

ARK Exchange Traded Funds (ETFs) have been in high demand and the ARK Genomic Revolution ETF (ARKG) is no different. The ETF invests in public equity markets across regions globally and in diversified sectors across growth and value stocks with diversified market caps.

The ETF has a cumulative funds inflow of over $5.5 billion and total assets under management (AUM) topping $8.9 billion. Teledoc is also the second highest holding in the ARK Genomic Revolution ETF with Pacific Biosciences of California, Inc taking top position.

Click logos to view shares

on EasyEquities

New call-to-actionNew call-to-actionNew call-to-action

Informed decisions

The U.S markets might be in for a rough ride as U.S political uncertainty and geopolitical tensions heat up until President-elect Biden takes office later this month. Long-term investing is key, and one should look through the madness to the shiny horizon.

New to investing

and want to see our recent Stock Picks?

Read: 3 Stock Pics to take you into the New Year!

Get these insights first & for free

Sources – EasyResearch, Teladoc Health Inc, NIO Limited, ARK INVEST, Barron’s, Benzinga, The Motley Fool, Koyfin.

Take note: stock data was taken on 11/01/2021 before the US market open.

Follow Barry Dumas

Barry image

Barry is a market analyst with GT247, with a wealth of experience in the investment markets. Now in his tenth year in the markets, Barry "The Beef" Dumas brings a combination of technical analysis and fundamental insights to the table

Any opinions, news, research, reports, analyses, prices, or other information contained within this research is provided by Barry Dumas, Market Analyst at GT247 (Pty) Ltd t/a (“”) as general market commentary, and does not constitute investment advice for the purposes of the Financial Advisory and Intermediary Services Act, 2002. First World Trader (Pty) Ltd t/a EasyEquities (“EasyEquities”) and do not warrant the correctness, accuracy, timeliness, reliability or completeness of any information received from third party data providers. You must rely solely upon your own judgment in all aspects of your investment and/or trading decisions and all investments and/or trades are made at your own risk. EasyEquities and (including any of their employees) will not accept any liability for any direct or indirect loss or damage, including without limitation, any loss of profit, which may arise directly or indirectly from use of or reliance on the market commentary. The content contained within is subject to change at any time without notice.The value of a financial product can go down, as well as up, due to changes in the value of the underlying investments. An investor may not recoup the full amount invested. Past performance is not necessarily an indication of future performance. These products are not guaranteed. Examples and/or graphs are for illustrative purposes only.